Lead optimisation of dehydroemetine for repositioned use in malaria.

Drug repositioning offers an effective alternative to de novo drug design to tackle the urgent need for novel antimalarial treatments. The antiamoebic compound emetine dihydrochloride has been identified as a potent in vitro inhibitor of the multidrug-resistant strain K1 of Plasmodium falciparum (50% inhibitory concentration (IC50), 47 nM +/- 2.1 nM (mean +/- standard deviation)). Dehydroemetine, a synthetic analogue of emetine dihydrochloride, has been reported to have lesscardiotoxic effects than emetine. The structures of two diastereomers of dehydroemetine were modeled on the published emetine binding site on the cryo-electron microscopy (cryo-EM) structure with PDB code 3J7A (P. falciparum 80S ribosome in complex with emetine), and it was found that (-)-R,S-dehydroemetine mimicked the bound pose of emetine more closely than did (-)-S,S-dehydroisoemetine. (-)-R,Sdehydroemetine (IC50 71.03 +/- 6.1 nM) was also found to be highly potent against the multidrug-resistant K1 strain of P. falciparum compared with ( -)-S,S-dehydroisoemetine (IC50, 2.07 +/- 0.26 mu M), which loses its potency due to the change of configuration at C-1'. In addition to its effect on the asexual erythrocytic stages of P. falciparum, the compound exhibited gametocidal properties with no cross-resistance against any of the multidrug-resistant strains tested. Drug interaction studies showed (-)-R,S-dehydroemetine to have synergistic antimalarial activity with atovaquone and proguanil. Emetine dihydrochloride and (-)-R,S-dehydroemetine failed to show any inhibition of the hERG potassium channel and displayed activity affecting the mitochondria! membrane potential, indicating a possible multimodal mechanism of action.